Projected Income Statement: Outlook Therapeutics, Inc.

Forecast Balance Sheet: Outlook Therapeutics, Inc.

Forecast Balance Sheet - Outlook Therapeutics, Inc.
Fiscal Period: September 2021 2022 2023 2024 2025 2026 2027 2028
Net Debt - - - - - - - -
Change - - - - - - - -
Announcement Date 22/12/21 29/12/22 22/12/23 27/12/24 19/12/25 - - -
Estimates

Cash Flow Forecast: Outlook Therapeutics, Inc.

Fiscal Period: September 2021 2022 2023 2026 2027 2028
CAPEX 1 - - - - - -
Change - - - - - -
Free Cash Flow (FCF) 1 - -56.67 -42.97 -46.75 -19.6 76.1
Change - - 24.18% - 58.07% 488.27%
Announcement Date 22/12/21 29/12/22 22/12/23 - - -
1USD in Million
Estimates

Forecast Financial Ratios: Outlook Therapeutics, Inc.

Fiscal Period: September 2020 2021 2022 2023 2024 2025 2026 2027 2028

Profitability

         
EBITDA Margin (%) - - - - - - - - -
EBIT Margin (%) - - - - - -4,746.07% -20,440.46% -75.32% 39.82%
EBT Margin (%) - - - - - -4,527.74% -25,801.53% -80.83% 13.81%
Net margin (%) - - - - - -4,417.91% -24,847.33% -101.45% 13.81%
FCF margin (%) - - - - - - -17,843.51% -44.75% 50.52%
FCF / Net Income (%) - - 85.8% 72.86% - - 71.81% 44.11% 365.81%

Profitability

         
ROA -123.12% -151.98% -153.56% -109.17% -146.64% -176.82% - - -
ROE 887.24% -1,430.33% -989.99% 2,069.13% 172.24% 118.61% - - -

Financial Health

         
Leverage (Debt/EBITDA) - - - - - - - - -
Debt / Free cash flow - - - - - - - - -

Capital Intensity

         
CAPEX / Current Assets (%) - - - - - - - - -
CAPEX / EBITDA (%) - - - - - - - - -
CAPEX / FCF (%) - - - - - - - - -

Items per share

         
Cash flow per share 1 - - - - - - - - -
Change - - - - - - - - -
Dividend per Share 1 - - - - - - - - -
Change - - - - - - - - -
Book Value Per Share 1 - 0.604 0.824 - - - - - -
Change - - 36.42% - - - - - -
EPS 1 - -7 -6.2 -4.8 -4.06 -1.79 -0.62 -0.19 0.075
Change - - 11.43% 22.58% 15.42% 55.91% 65.36% 69.35% 139.47%
Nbr of stocks (in thousands) - 8,767 11,307 13,012 23,656 44,420 243,448 243,448 243,448
Announcement Date - 22/12/21 29/12/22 22/12/23 27/12/24 19/12/25 - - -
1USD
Estimates
2026 *2027 *
P/E -0.65x -2.11x
PBR - -
EV / Sales 373x 2.23x
Yield - -

EPS & Dividend

EPS & Dividend - Outlook Therapeutics, Inc.


Y-o-Y evolution of P/E

Valuation ratios - P/E - Outlook Therapeutics, Inc.
 
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Outlook Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.4010USD
Average target price
4.820USD
Spread / Average Target
+1,102.00%
  1. Stock Market
  2. Stocks
  3. OTLK Stock
  4. Financials Outlook Therapeutics, Inc.